NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity ...

Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's ...

UBS has reiterated its Buy rating and $1,050 price target on LLY stock, highlighting the company’s growing dominance in the ...

The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...

AON, a health insurance consultant, and Murphy Administration officials announced on Wednesday that premiums in the State ...

Economists around the world are expecting muted U.S. economic growth in coming quarters, and some indicators suggest a mild recession is a possibility. It may become difficult for investors to ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...

Ireland has long been a global pharmaceutical powerhouse, hosting more than 90 pharmaceutical companies and employing around ...

The weight-loss drug boom has dominated headlines for the last two years — but underneath the hype lies a major flaw in the ...

Top-Line Data Expected in the Fourth Quarter of 2025 CAMBRIDGE, Mass., July 9, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology ...

Touro University Nevada is asking for volunteers to take part in a study on the long-term effects of injectable weight-loss or diabetic medication.